The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Triplet combinations in FLT3-mutated AML
Shai Shimony , MD, Dana-Farber Cancer Institute, Boston, MA, discusses the efficacy of triplet combinations in FLT3-mutated acute myeloid leukemia (AML), both in the frontline setting and in the relapsed/refractory (R/R) setting. Dr Shimony also highlights the importance of obtaining longer follow-up data on these combinations to better understand durability of response. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
